Cargando…

A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by an accumulation of glycosaminoglycans (GAGs), including heparan sulfate, in the body. Major manifestations involve the central nerve system (CNS), skeletal deformation, and visceral manifestations. About 30% of M...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashima, Ryuichi, Ohira, Mari, Okuyama, Torayuki, Onodera, Masafumi, Takada, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185571/
https://www.ncbi.nlm.nih.gov/pubmed/37188686
http://dx.doi.org/10.1038/s41598-023-34541-w
_version_ 1785042384711581696
author Mashima, Ryuichi
Ohira, Mari
Okuyama, Torayuki
Onodera, Masafumi
Takada, Shuji
author_facet Mashima, Ryuichi
Ohira, Mari
Okuyama, Torayuki
Onodera, Masafumi
Takada, Shuji
author_sort Mashima, Ryuichi
collection PubMed
description Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by an accumulation of glycosaminoglycans (GAGs), including heparan sulfate, in the body. Major manifestations involve the central nerve system (CNS), skeletal deformation, and visceral manifestations. About 30% of MPS II is linked with an attenuated type of disease subtype with visceral involvement. In contrast, 70% of MPS II is associated with a severe type of disease subtype with CNS manifestations that are caused by the human iduronate-2-sulfatase (IDS)-Pro86Leu (P86L) mutation, a common missense mutation in MPS II. In this study, we reported a novel Ids-P88L MPS II mouse model, an analogous mutation to human IDS-P86L. In this mouse model, a significant impairment of IDS enzyme activity in the blood with a short lifespan was observed. Consistently, the IDS enzyme activity of the body, as assessed in the liver, kidney, spleen, lung, and heart, was significantly impaired. Conversely, the level of GAG was elevated in the body. A putative biomarker with unestablished nature termed UA-HNAc(1S) (late retention time), one of two UA-HNAc(1S) species with late retention time on reversed-phase separation,is a recently reported MPS II-specific biomarker derived from heparan sulfate with uncharacterized mechanism. Thus, we asked whether this biomarker might be elevated in our mouse model. We found a significant accumulation of this biomarker in the liver, suggesting that hepatic formation could be predominant. Finally, to examine whether gene therapy could enhance IDS enzyme activity in this model, the efficacy of the nuclease-mediated genome correction system was tested. We found a marginal elevation of IDS enzyme activity in the treated group, raising the possibility that the effect of gene correction could be assessed in this mouse model. In conclusion, we established a novel Ids-P88L MPS II mouse model that consistently recapitulates the previously reported phenotype in several mouse models.
format Online
Article
Text
id pubmed-10185571
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101855712023-05-17 A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation Mashima, Ryuichi Ohira, Mari Okuyama, Torayuki Onodera, Masafumi Takada, Shuji Sci Rep Article Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by an accumulation of glycosaminoglycans (GAGs), including heparan sulfate, in the body. Major manifestations involve the central nerve system (CNS), skeletal deformation, and visceral manifestations. About 30% of MPS II is linked with an attenuated type of disease subtype with visceral involvement. In contrast, 70% of MPS II is associated with a severe type of disease subtype with CNS manifestations that are caused by the human iduronate-2-sulfatase (IDS)-Pro86Leu (P86L) mutation, a common missense mutation in MPS II. In this study, we reported a novel Ids-P88L MPS II mouse model, an analogous mutation to human IDS-P86L. In this mouse model, a significant impairment of IDS enzyme activity in the blood with a short lifespan was observed. Consistently, the IDS enzyme activity of the body, as assessed in the liver, kidney, spleen, lung, and heart, was significantly impaired. Conversely, the level of GAG was elevated in the body. A putative biomarker with unestablished nature termed UA-HNAc(1S) (late retention time), one of two UA-HNAc(1S) species with late retention time on reversed-phase separation,is a recently reported MPS II-specific biomarker derived from heparan sulfate with uncharacterized mechanism. Thus, we asked whether this biomarker might be elevated in our mouse model. We found a significant accumulation of this biomarker in the liver, suggesting that hepatic formation could be predominant. Finally, to examine whether gene therapy could enhance IDS enzyme activity in this model, the efficacy of the nuclease-mediated genome correction system was tested. We found a marginal elevation of IDS enzyme activity in the treated group, raising the possibility that the effect of gene correction could be assessed in this mouse model. In conclusion, we established a novel Ids-P88L MPS II mouse model that consistently recapitulates the previously reported phenotype in several mouse models. Nature Publishing Group UK 2023-05-15 /pmc/articles/PMC10185571/ /pubmed/37188686 http://dx.doi.org/10.1038/s41598-023-34541-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mashima, Ryuichi
Ohira, Mari
Okuyama, Torayuki
Onodera, Masafumi
Takada, Shuji
A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
title A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
title_full A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
title_fullStr A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
title_full_unstemmed A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
title_short A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
title_sort novel mucopolysaccharidosis type ii mouse model with an iduronate-2-sulfatase-p88l mutation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185571/
https://www.ncbi.nlm.nih.gov/pubmed/37188686
http://dx.doi.org/10.1038/s41598-023-34541-w
work_keys_str_mv AT mashimaryuichi anovelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT ohiramari anovelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT okuyamatorayuki anovelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT onoderamasafumi anovelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT takadashuji anovelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT mashimaryuichi novelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT ohiramari novelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT okuyamatorayuki novelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT onoderamasafumi novelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation
AT takadashuji novelmucopolysaccharidosistypeiimousemodelwithaniduronate2sulfatasep88lmutation